Ruth has been Senior Lecturer in the Department of General Practice since 2009. She undertakes research in adverse drug reaction monitoring (pharmacovigilance) and rational prescribing and has experience in pharmacoepidemiology studies.
Ruth is responsible for part of the undergraduate general practice teaching modules and is also involved in postgraduate teaching to general practitioners and other health professionals where she emphasises the need to recognize adverse drug reactions and strategies to avoid them or minimise the harm they may cause. The relevance of her teaching and research to clinical practice is in large part due to her extensive clinical experience primarily in rural general practice and also rheumatology.
Ruth is also Senior Medical Assessor in the Centre for Adverse Reactions Monitoring (CARM), New Zealand Pharmacovigilance Centre, Dept of Preventive and Social Medicine, University of Otago, Dunedin where a high proportion of the suspected adverse reaction reports submitted by health professionals are from primary care. She is also an expert advisor to the New Zealand Medicines Adverse Reactions Committee.
As a consultant to the Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden Ruth also undertakes research and provides training in international pharmacovigilance.
Research Interests
Pharmacovigilance and Rational Prescribing
Detection of previously unrecognized adverse drug reactions (ADRs) and interactions in national and international databases of ADR reports.
Assessing if the outputs from automated methods of detecting suspected adverse reactions from large databases are clinically relevant.
Assessment of ADR case reports to determine risk factors for individual ADRs.
Assessment of ADR case reports to determine if prescribing behaviour has allowed specific ADRs or interactions to occur and how this can be modified.
Lucy Peterson Topic: Reducing barriers to practice nurse involvement in general cervical screening and understanding effective methods of inviting and engaging priority women in cervical screening in general practice. Supervisors Ruth Savage, Kim Burgess, Jackie Cooper Sponsor: Partnership Health Canterbury PHO
Savage, R., Lee, J., & Tatley, M. (2023). Impact of general practice on medicine and vaccine safety in New Zealand. Australian Journal of General Practice, (Suppl. 2), (pp. 238). Retrieved from https://www1.racgp.org.au/ajgp/home
Conference Contribution - Published proceedings: Abstract
Gauffin, O., Brand, J. S., Vidlin, S. H., Sartori, D., Asikainen, S., Català, M., … Savage, R., … Norén, G. N. (2023). Supporting pharmacovigilance signal validation and prioritization with analyses of routinely collected health data: Lessons learned from an EHDEN Network study. Drug Safety. Advance online publication. doi: 10.1007/s40264-023-01353-w
Journal - Research Article
Savage, R. L. (2023). Empagliflozin and necrotising fasciitis of the perineum (Fournier’s gangrene): Potential risk factors in New Zealand adverse reaction reports. Proceedings of the New Zealand Primary Health Care, General Practice & Rural Health Research Symposium. (pp. 10). Retrieved from https://www.otago.ac.nz/wellington/departments/primaryhealthcaregeneralpractice
Conference Contribution - Published proceedings: Abstract
Rudolph, A., & Savage, R. (2023). Vulval aphthous ulcers in adolescents following COVID-19 vaccination: Analysis of an international case series. Journal of Pediatric & Adolescent Gynecology, 36, 383-392. doi: 10.1016/j.jpag.2023.03.006
Journal - Research Article
Savage, R. L. (2022). The value of complementary approaches to causality assessment for individual case safety reports: The example of Artemisia annua and hepatotoxicity. In J. Barnes (Ed.), Pharmacovigilance for herbal and traditional medicines. (pp. 211-220). Cham, Switzerland: Springer. doi: 10.1007/978-3-031-07275-8
Chapter in Book - Research
Savage, R., Vidlin, S. H., Grundmark, B., Rocca, E., & Gauffin, O. (2021). Remdesivir and renal injury: Interpreting global case safety reports in the context of COVID-19 infection. Proceedings of the 6th Pharmacoepidemiology Research Network Symposium. (pp. 11-12). Retrieved from https://www.otago.ac.nz/pharmacoepidemiology
Conference Contribution - Published proceedings: Abstract
Wilson, G., Windner, Z., Bidwell, S., Dowell, A., Toop, L., Savage, R., & Hudson, B. (2021). Navigating the health system during COVID-19: Primary care perspectives on delayed patient care. New Zealand Medical Journal, 134(1546), 17-27. Retrieved from https://www.nzma.org.nz/journal
Journal - Research Article
Wilson, G., Windner, Z., Bidwell, S., Currie, O., Dowell, A., Halim, A. A., Toop, L., Savage, R., Ranaweera, U., Beadel, H., & Hudson, B. (2021). 'Here to stay': Changes to prescribing medication in general practice during the COVID-19 pandemic in New Zealand. Journal of Primary Health Care, 13(3), 222-230. doi: 10.1071/hc21035
Journal - Research Article
Rocca, E., Gauffin, O., Savage, R., Vidlin, S. H., & Grundmark, B. (2021). Remdesivir in the COVID-19 pandemic: An analysis of spontaneous reports in VigiBase during 2020. Drug Safety, 44, 987-998. doi: 10.1007/s40264-021-01091-x
Journal - Research Article
Wilson, G., Currie, O., Bidwell, S., Saeed, B., Dowell, A., Halim, A. A., Toop, L., Richardson, A., Savage, R., & Hudson, B. (2021). Empty waiting rooms: The New Zealand general practice experience with telehealth during the COVID-19 pandemic. New Zealand Medical Journal, 134(1538), 89-101. Retrieved from https://www.nzma.org.nz/journal
Journal - Research Article
Russom, M., Fitsum, Y., Abraham, A., & Savage, R. L. (2021). Diclofenac and the risk of rhabdomyolysis: Analysis of publications and the WHO Global Pharmacovigilance Database. Drugs: Real World Outcomes, 8, 263-275. doi: 10.1007/s40801-021-00240-z
Journal - Research Article
Bennett, M., Chang, C. L., Tatley, M., Savage, R., & Hancox, R. J. (2021). The safety of cardio-selective beta1-blockers in asthma: Literature review and search of global pharmacovigilance safety reports. ERJ Open Research, 7, 1-10. doi: 10.1183/23120541.00801-2020
Journal - Research Other
Hegerius, A., Caduff-Janosa, P., Savage, R., & Ellenius, J. (2020). E-learning in pharmacovigilance: An evaluation of microlearning-based modules developed by Uppsala Monitoring Centre. Drug Safety, 43, 1171-1180. doi: 10.1007/s40264-020-00981-w
Journal - Research Article
Savage, R. L., Hill, G. R., Barnes, J., Kenyon, S. H., & Tatley, M. V. (2019). Suspected hepatotoxicity with a supercritical carbon dioxide extract of Artemisia annua in grapeseed oil used in New Zealand [Brief research report article]. Frontiers in Pharmacology, 10, 1448. doi: 10.3389/fphar.2019.01448
Journal - Research Other
Kuan, I. H. S., Savage, R. L., Duffull, S. B., Walker, R. J., & Wright, D. F. B. (2019). The association between metformin therapy and lactic acidosis. Drug Safety, 42, 1449-1469. doi: 10.1007/s40264-019-00854-x
Journal - Research Article
Storey, M., Savage, R., Stenlund, J., Tatley, M., & Kenyon, S. (2018). Using the M2 scheme to investigate safety signals. Proceedings of the 4th Pharmacoepidemiology Research Network Symposium. (pp. 12). Retrieved from https://www.otago.ac.nz/pharmacoepidemiology
Conference Contribution - Published proceedings: Abstract
Savage, R. L., Tatley, M., & Barnes, J. (2018). Hepatotoxicity with a natural dietary supplement, Artemisia annua L. extract in grapeseed oil. New Zealand Pharmacovigilance Centre Reports. Drug Safety, 41(11), (pp. 1151). doi: 10.1007/s40264-018-0719-2
Conference Contribution - Published proceedings: Abstract
Hegerius, A., Caduff, P., Savage, R., & Ellenius, J. (2018). Anywhere, anytime: Distance learning in pharmacovigilance. Drug Safety, 41(11), (pp. 1109). doi: 10.1007/s40264-018-0719-2
Conference Contribution - Published proceedings: Abstract
Kuan, I. H. S., Duffull, S. B., Savage, R. L., & Wright, D. F. B. (2018, August). Should we use metformin in patients with chronic renal impairment? A systematic review of published metformin associated lactic acidosis cases. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L., & Tatley, M. V. (2018). Case series analysis of New Zealand reports of rapid intense potentiation of warfarin by roxithromycin [Short communcation]. Drug Safety, 41(5), 515-521. doi: 10.1007/s40264-017-0634-y
Journal - Research Other
Savage, R., & Tatley, M. (2017). Rapid onset of very high INR values when roxithromycin prescribed with warfarin challenges the accepted mechanism. Drug Safety, 40(10), (pp. 963-964). doi: 10.1007/s40264-017-0580-8
Conference Contribution - Published proceedings: Abstract
Savage, R., Tatley, M., & Kunac, D. (2017, July). Fifty years of adverse drug reaction reporting in New Zealand: Primary care involvement and the developing use of e-health. Verbal presentation at the Royal New Zealand College of General Practitioners (RNZCGP) Conference for General Practice Quality Symposium, Dunedin, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L., Castellano, M., & Tatley, M. V. (2017). International reports of unexpected low plasma concentrations of dabigatran suggest that more frequent measurements will add value. Seminars in Thrombosis & Hemostasis, 43(6), 635-638. doi: 10.1055/s-0037-1603361
Journal - Research Other
Castellano, M., Sartori, D., & Savage, R. (2016). Dabigatran and thromboembolism: Analysis of case histories for risk factors. WHO Pharmaceuticals Newsletter, 3, 15-22. Retrieved from http://www.who.int/medicines/publications/newsletter/en/
Journal - Research Other
Savage, R., Star, K., Zekarias, A., Persson Brobert, G., Ansell, D., & Edwards, I. R. (2016). Prescribing and diagnostic issues associated with sumatriptan identified through open-ended screening for safety signals in electronic health care records. Drug Safety, 39(10), (pp. 1014-1015). doi: 10.1007/s40264-016-0445-6
Conference Contribution - Published proceedings: Abstract
Tatley, M., Savage, R., Kunac, D., & Ashton, J. (2016). Years of pharmacovigilance in New Zealand: Lessons in sustainability and growth. Drug Safety, 39(10), (pp. 1001). doi: 10.1007/s40264-016-0445-6
Conference Contribution - Published proceedings: Abstract
Savage, R., Clark, P., & Tatley, M. (2016). Taking a fresh look at identifying and responding to drug-induced illness. Proceedings of the Royal New Zealand College of General Practitioners (RNZCGP) Conference for General Practice. Retrieved from http://www.generalpractice.org.nz/gp16
Conference Contribution - Published proceedings: Abstract
Maggo, S. D. S., Savage, R. L., & Kennedy, M. A. (2016). Impact of new genomic technologies on understanding adverse drug reactions. Clinical Pharmacokinetics, 55(4), 419-436. doi: 10.1007/s40262-015-0324-9
Journal - Research Article
Wells, J. E., Cross, N. B., Savage, R. L., Parkin, L., Horsburgh, S., & Richardson, A. K. (2015). Renal replacement therapy associated with lithium nephrotoxicity in New Zealand. New Zealand Medical Journal, 128(1425). Retrieved from http://www.nzma.org.nz/journal
Journal - Research Other
Savage, R., & Tatley, M. (2015). Comparison of New Zealand and international spontaneous reports of adverse reactions occurring within one week of zoledronic acid infusion with the information in New Zealand product data sheets. In J. Young (Ed.), Proceedings of the Annual General Practice and Primary Care Research Weekend. (pp. 27-28). Dunedin, New Zealand: Department of General Practice and Rural Health, University of Otago. [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. L., Zekarias, A., & Caduff-Janosa, P. (2015). Varenicline and abnormal sleep related events. Sleep, 38(5), 833-837. doi: 10.5665/sleep.4686
Journal - Research Article
Savage, R. L., Zekarias, A., & Caduff-Janosa, P. (2014). Varenicline and abnormal sleep-related events. Drug Safety, 37(10), (pp. 878-879). doi: 10.1007/s40264-014-0208-1
Conference Contribution - Published proceedings: Abstract
Savage, R. (2014, August). Varenicline and abnormal sleep-related events. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L. (2013). The New Zealand Centre for Adverse Reactions Monitoring: A source of practice-based evidence. Clinical Therapeutics, 35(8, Suppl.), (pp. e128). doi: 10.1016/j.clinthera.2013.07.400
Conference Contribution - Published proceedings: Abstract
Savage, R. (2013, October). Varenicline and abnormal sleep-related events. Verbal presentation at the Hanmer Springs Research Weekend, Hanmer Springs, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Sallstedt, L., Watson, S., Savage, R. L., & Zekarias, A. (2013). Follow up of UMC signals. Drug Safety, 36(9), (pp. 888). doi: 10.1007/s40264-013-0087-x
Conference Contribution - Published proceedings: Abstract
Kennedy, M. A., Chua, E. W., Macmil, S., Foulds, J., Barclay, M., Savage, R., … Miller, A. (2013, August). Genomic medicine and adverse drug reactions. Verbal presentation at the Queenstown Molecular Biology (QMB) Meetings, Queenstown, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Chua, E. W., Macmil, S., Foulds, J., Barclay, M., Savage, R., Helsby, N. A., Miller, A., & Kennedy, M. A. (2013, August). Understanding adverse Drug Reactions or responses Using Genomic Sequencing (UDRUGS). Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L. (2013). The New Zealand centre for adverse drug reactions monitoring: A source of practice-based evidence. Clinical Therapeutics, 35(8 (Suppl.)), (pp. e128). doi: 10.1016/j.clinthera.2013.07.400
Conference Contribution - Published proceedings: Abstract
Savage, R. (2013). The New Zealand Centre for Adverse Reactions Monitoring: A source of practice-based evidence. Journal of Primary Health Care, 5(2), 170-173. doi: 10.1071/HC13170
Journal - Research Other
Kennedy, M. A., Chua, E. W., Barclay, M. L., & Savage, R. (2012, November). Growing a New Zealand biobank (UDRUGS) to allow genetic analysis of rare, serious adverse drug reactions and unusual drug responses. Verbal presentation at the 8th Annual Carney Pharmacogenomics Symposium, Christchurch, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L., Star, K., & Hill, R. (2012). Severe muscle symptoms with lipid-lowering agents may be confused with neurogenic claudication associated with spinal canal stenosis. International Journal of Risk & Safety in Medicine, 24(4), 215-219. doi: 10.3233/jrs-2012-0577
Journal - Research Article
Savage, R. (2012). Proposal from the New Zealand Pharmacovigilence Centre for a GPEP1 module in adverse drug reaction monitoring and safe and rational prescribing. Proceedings of the Royal New Zealand College of General Practitioners (RNZCGP) Conference for General Practice: Through Patients' Eyes. Retrieved from http://www.conference.co.nz/gp12/programme/index
Conference Contribution - Published proceedings: Abstract
Savage, R. (2012, August). Evaluation of 10 years of drug-related hyponatraemia reports in the New Zealand Centre for Adverse Reactions Monitoring (CARM) database, 2001-2010. Verbal presentation at the Primary Care and General Practice Research Weekend, Martinborough, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Harrison-Woolrych, M., Maggo, S., Tan, M., Savage, R., & Ashton, J. (2012). Cardiovascular events in patients taking varenicline: A case series from intensive postmarketing surveillance in New Zealand. Drug Safety, 35(1), 33-43. doi: 10.2165/11597690-000000000-00000
Journal - Research Article
Savage, R. (2010, September). Is statin-induced rhabdomyolysis avoidable? An example of preventability assessment from the CARM database. Verbal presentation at the New Zealand General Practitioners Conference Research Day: Doing the Right Thing, Christchurch, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. (2010). Is statin-induced rhabdomyolysis avoidable? An example of preventability assessment from the CARM database. Proceedings of the New Zealand General Practitioners Conference: Doing the right thing. (pp. 45). Retrieved from http://www.conference.co.nz/rnzcgp10/programme
Conference Contribution - Published proceedings: Abstract
Savage, R. (2010, November). Etoricoxib & NSAID guidelines. Verbal presentation at the GP Research Weekend, Dunedin, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L. (2010). Can serious drug-related hyponatraemia be avoided? Changing patterns in spontaneous reports of medicine-related hyponatraemia lead to new prescribing advice. Drug Safety.33(10), (pp. 943). [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. L. (2010). Is statin-induced rhabdomyolysis avoidable? An example of preventability assessment from the New Zealand Pharmacovigilance Centre. Drug Safety.33(10), (pp. 952). [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. L. (2010). Leflunomide in combination therapy for rheumatoid arthritis [Editorial]. Drug Safety, 33(6), 523-526. doi: 10.2165/11532390-000000000-00000
Journal - Research Other
James, C. M., Tatley, M., Savage, R., Kenyon, S. H., & Jessamine, S. (2009). Eltroxin formulation change: The New Zealand experience. Drug Safety, 32(10), (pp. 900). [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. (2009, October). Identification and analysis of preventable adverse drug events in primary care through reports to the Centre for Adverse Reactions Monitoring (CARM). Verbal presentation at the Waitomo General Practitioners Research Weekend, Waitomo, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. (2009, September). Can severe medicine-related hyponatraemia be avoided. Verbal presentation at the Royal New Zealand College of General Practitioners Annual Scientific Conference: Myths and Realities of Primary Care, Wellington, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L. (2009, September). Changing patterns in spontaneous reports of medicine-related hyponatraemia. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting, Dunedin, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L., Kunac, D. L., & Johansson, J. (2009). Appraising the post-marketing safety of medicines: A description of national and international pharmacovigilance with a focus on medicines used in chronic pain. Current Anaesthesia & Critical Care, 20(5-6), 215-220. doi: 10.1016/j.cacc.2009.07.013
Journal - Research Article
Maggo, S., Savage, R., Ashton, J. A., & Clark, D. W. G. (2008). Retrospective analysis of psychiatric effects reported for HMG-COA reductase inhibitors (STATINS) at the NZPHVC. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting. ASCEPT. Retrieved from http://phal.otago.ac.nz/ascept_docos/programme%202008.pdf
Conference Contribution - Published proceedings: Abstract
Savage, R. (2008). Emerging safety signals for leflunomide from a regulatory review. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Annual Scientific Meeting. ASCEPT. Retrieved from http://phal.otago.ac.nz/ascept_docos/programme%202008.pdf
Conference Contribution - Published proceedings: Abstract
Meyboom, R. H. B., Star, K., Bate, J., Savage, R., & Edwards, I. R. (2008). TNF-α inhibitors and leukaemia: International pharmacovigilance reports [Letter to the editor]. Drug Safety, 31(5), 445-447. doi: 10.2165/00002018-200831050-00013
Journal - Research Other
Gwynne Jones, D. P., Savage, R. L., & Highton, J. (2008). Alendronate-induced synovitis. Journal of Rheumatology, 35(3), 537-538.
Journal - Research Article
Savage, R. L., & Tatley, M. (2007). Pancreatitis with serious sequelae in patients taking ezetimibe. Drug Safety, 30(10). [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. (2007, December). The safety of Rosiglitazone and other Thaizolidinediones: Signals of paradoxical adverse reactions from national and international spontaneous reports. Festschrift in honour of Associate Professor David Clark: An international symposium on New Zealand's crucial role in monitoring/improving the safety of medicines. Dunedin, New Zealand. [Public Seminar].
Other Research Output
Savage, R. L. (2007, August-September). Emerging safety signals for leflunomide from a systemic analysis of spontaneous reporting systems, publications and international regulation. Verbal presentation at the New Zealand Rheumatology Association Conference, Dunedin, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Tatley, M., & Savage, R. (2007). Psychiatric adverse reactions with statins, fibrates and ezetimibe: Implications for the use of lipid-lowering agents. Drug Safety, 30(3), 195-201.
Journal - Research Article
Meuli, K. A., Stamp, L. K., O'Donnell, J. L., Savage, R. L., & Chapman, P. T. (2007). Leflunomide-associated infections in RA. Internal Medicine Journal.37(Suppl. 2), (pp. A48). [Abstract]
Conference Contribution - Published proceedings: Abstract
Jenks, K. A., Stamp, L. K., O'Donnell, J. L., Savage, R. L., & Chapman, P. T. (2007). Leflunomide-associated infections in rheumatoid arthritis. Journal of Rheumatology, 34, 2201-2203.
Journal - Research Article
Savage, R. (2006). Interstitial nephritis with PPIs on the rise. New Zealand Doctor, (October), 22.
Journal - Professional & Other Non-Research Articles
Savage, R. L., Highton, J., Boyd, I. W., & Chapman, P. (2006). Pneumonitis associated with leflunomide: A profile of New Zealand and Australian reports. Internal Medicine Journal, 36, 162-169.
Journal - Research Article
Savage, R. L., & Tatley, M. (2006). Method for developing an adverse reaction profile for a medicine using national and international spontaneous reports. Drug Safety.29(10), (pp. 964). [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. (2005). Thiazolidinediones and lowered high density lipoprotein cholesterol. WHO Signal, February, 6-8.
Journal - Research Article
Savage, R. L., Coulter, D. M., & Harrison-Woolrych, M. (2005). COX-2 inhibitors may cause dysrrhythmias: A signal from the New Zealand Intensive Medicines Monitoring Programme. Drug Safety.28(10), (pp. 963). [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. L., Highton, J., Boyd, I. W., & Chapman, P. T. (2005, September). Pneumonitis with leflunomide: A profile of New Zealand and Australian reports. Verbal presentation at the New Zealand Rheumatology Association in conjunction with NZ Health Professionals in Rheumatology Annual Scientific Meeting, Palmerston North, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L., & Kiuru, A. (2005, August). Rosiglitazone and lowered HDL cholesterol. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Scientific Meeting, Wellington, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L. (2005, August). Tramadol and hepatitis: A signal from spontaneous reports. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Scientific Meeting, Wellington, New Zealand.
Conference Contribution - Verbal presentation and other Conference outputs
Ng, J., Savage, R., & McQueen, F. (2005). Churg-Strauss vasculitis syndrome and leukotriene receptor antagonists [Research Letter]. Annals of the Rheumatic Diseases, 64, 1382.
Journal - Research Other
Savage, R. L., & Kiuru, A. (2005). Thiazolidinediones and lowered HDL cholesterol [Research Letter]. Diabetes Care, 28(9), 2329-2330.
Journal - Research Other
Savage, R. L., & Kiuru, A. (2005). Rosiglitazone and lowered high density lipoprotein cholesterol. Drug Safety.28(10), (pp. 950). [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. L., Star, K., & Edwards, I. R. (2005). Is rofecoxib different and do COX-2 inhibitors have advantages over standard NSAIDS? An analysis of international voluntary adverse reaction reports. Drug Safety.28(10), (pp. 950). [Abstract]
Conference Contribution - Published proceedings: Abstract
Gwynne Jones, D., Savage, R., & Highton, J. (2005). Synovitis induced by alendronic acid can present as acute carpal tunnel syndrome. BMJ, 330, 7482, 74. doi: 10.1136/bmj.330.7482.74
Journal - Research Article
Savage, R. (2005). Cyclo-oxygenase-2 inhibitors: When should they be used in the elderly? Drugs & Aging, 22(3), 185-200.
Journal - Research Article
Savage, R. L., Highton, J., Chapman, P. T., & Boyd, I. W. (2004). Severe pneumonitis with leflunomide: Features of reports from New Zealand and Australia. Clinical and Experimental Pharmacology and Physiology.31(Suppl.), (pp. A232). [Abstract]
Conference Contribution - Published proceedings: Abstract
Ericsson, J., Savage, R., Farah, M., & Meyboom, R. (2004, October). Failure of oral contraceptives during the use of hypericum-containing drugs. Poster session presented at the 4th Annual Meeting of the International Society of Pharmacovigilance, Dublin, Ireland.
Conference Contribution - Poster Presentation (not in published proceedings)
Savage, R. (2004). Can infliximab aggravate a silent breast cancer? Commissioned by World Health Organisation (WHO) Signal, June 2004. Sweden: Uppsala Monitoring Centre. 3p.
Commissioned Report for External Body
Savage, R. L., Highton, J., Chapman, P. T., & Boyd, I. W. (2004). Severe pneumonitis with leflunomide: New Zealand and Australian adverse reaction reports. Poster session presented at the Clinical Pharmacology and Therapeutics International Meeting, Brisbane, Australia.
Conference Contribution - Poster Presentation (not in published proceedings)
Savage, R. L. (2003, August). How pharmacovigilance contributes to quality use of medicines. Verbal presentation at the ASCEPT Scientific Meeting, Wellington, New Zealand. Geneva, Switzerland: World Health Organization.
Conference Contribution - Verbal presentation and other Conference outputs
Savage, R. L., & Boyd, I. W. (2003). Administration error may be the cause of severe back pain with intravenous amiodarone. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Scientific Meeting. Wellington, New Zealand. [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. L. (2003, February). Experience of international drug monitoring. Verbal presentation at the International Workshop on Pharmacoepidmiology, Otago Museum, Dunedin, New Zealand. Geneva, Switzerland: World Health Organization.
Conference Contribution - Verbal presentation and other Conference outputs
Coulter, D. M., Clark, D. W., & Savage, R. (2003). Celecoxib, rofecoxib, and acute temporary visual impairment. British Medical Journal, 327, 1214-1215.
Journal - Research Article
Pettersson, M., & Savage, R. L. (2002). Cyclo-oxygenase 2 inhibitors and sudden death. Drugs of Current Interest, (December). USA: Uppsala Monitoring Centre.
Journal - Professional & Other Non-Research Articles
Savage, R., & Uppsala Monitoring Centre. (2002). COX-2 Inhibitors and sudden death. Drugs of Current Interest - Abstracts. (pp. 15). Sweden: the Uppsala Monitoring Centre. [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. (2002). Loratadine. WHO Pharmaceuticals Newsletter, (2), 12.
Journal - Research Article
Savage, R. (2002). Proton pump inhibitors. WHO Pharmaceuticals Newsletter, (2), 12.
Journal - Research Article
Savage, R., Boyd, I., & Coulter, D. M. (2001). Celecoxib and tricyclic antidepressants (TCAs). Report of the 24th Annual Meeting of Representatives of the National Centres participating in the WHO International Drug Monitoring Programme. (pp. 10). Dunedin, New Zealand: WHO. [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R. L., Boyd, I., & Coulter, D. (2001). Celecoxib: An adverse reaction profile. Proceedings of the Australian Society of Clinical and Experimental Pharmacologists and Toxicologists Annual Scientific Meeting.9, (pp. 51). Dunedin, New Zealand. [Abstract]
Conference Contribution - Published proceedings: Abstract
Savage, R., & Coulter, D. M. (2000). Oral contraceptives and venous thromboembolism [Letter]. New Ethicals Journal, 24.
Journal - Research Article
Savage, R. (2000). Omeprazole-induced interstitial nephritis. Prescriber Update, 20, 11-13. Retrieved from https://www.moh.govt.nz
Journal - Research Other
Savage, R. (1997). Oral contraceptives and venous thromboembolism [Letter]. New Zealand Medical Journal, 107, 109.
Journal - Research Other
The ADR Signals Analysis Project (ASAP) Team, including Savage, R. (1997). How does cystitis affect a comparative risk profile of tiaprofenic acid with other nonsteroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. Pharmacology & Toxicology, 80(5), 211-217. doi: 10.1111/j.1600-0773.1997.tb01962.x
Journal - Research Article
Savage, R. (1997). Current debate: Oral contraceptives and venous thromboembolism. PreMec Bulletin, November.
Journal - Research Other
